CTOs on the Move

Park Place Behavioral Health Care

www.ppbh.org

 
Park Place Behavioral Health Care is a Kissimmee, FL-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
  • Number of Employees: 100-250
  • Annual Revenue: $10-50 Million
  • www.ppbh.org
  • 206 Park Place Blvd
    Kissimmee, FL USA 34741
  • Phone: 407.846.0023

Executives

Name Title Contact Details

Similar Companies

Cancer Nutrition Centers

Cancer Nutrition Centers is a Arlington Heights, IL-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Meadows Regional Medical Center

Meadows Regional Medical Center is one of the leading companies in Healthcare, Pharmaceuticals, and Biotech industry. Meadows Regional Medical Center is based in Vidalia, GA. You can find more information on Meadows Regional Medical Center at www.meadowsregional.org

Carefor Health and Community Services

Since 1897, Carefor® Health & Community Services, a registered charity, has been keeping families together longer at home by providing home health care and community support services.

Governance Institute, The

Governance Institute, The is a San Diego, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

KaloBios

KaloBios is a biopharmaceutical company dedicated to helping the lives of patients with innovative therapies. Our mission is to improve the lives of cancer patients with innovative, Humaneered®, monoclonal antibodies. KaloBios` Humaneered® antibodies are next generation, customized antibodies designed to overcome challenges limiting today`s marketed antibody products. Using our expertise, our antibodies are customized to enhance a desired effect or reduce a possible undesired effect. Our pipeline is comprised of Humaneered® antibodies. These antibodies are being investigated in clinical development programs focused on treating cancer: KB004 (anti-EphA3) Humaneered® mAb to treat patients with hematologic malignancies, solid tumors, and their stem cells; currently enrolling patients with myelofibrosis and myelodysplastic syndrome in the company’s Phase 2 expansion portion of its Phase 1/2 clinical trial in hematologic malignancies; and KB003 (anti-GM-CSF) Humaneered® mAb that KaloBios intends to evaluate in oncology indications where GM-CSF may play a key role in such indications as chronic myelomonocytic leukemia (CMML). KaloBios intends to commence clinical evaluation of KB003 in this patient population beginning in the second half of 2015. We use a patient-targeted approach utilizing or developing a screen or diagnostic method to identify those patients most likely to benefit from our treatments.